Synthetic Biologics SYN-004 Oral Enzyme for C. difficile prevention

* In the news  31 March 2014 *
Prevention of C. difficile (C. diff.) Infections – SYN-004 Oral Enzyme

Manufacturing is underway to support preclinical and clinical trials of SYN-004,  Synthetic Biologics’ lead anti-infective product candidate, which is believed to be the first and only therapy designed to potentially prevent the devastating effects of C. diff. The Center for Disease Control and Prevention (CDC) has classified C. diff as an “urgent public health threat”[ii], surpassing Methicillin-resistant Staphylococcus aureus (MRSA) as the number one hospital-acquired infection in the United States. C. diff is a multidrug-resistant bacterium that infects 1.1 million U.S. patients annually[iii]. Plans remain on schedule to initiate a 28-day bridging toxicology study of the Company’s second generation candidate late in the second quarter of 2014. Synthetic Biologics expects to file an IND and to initiate Phase Ia and Ib clinical trials during the second half of 2014 for its C. diff program.

 

To read the article in its entirety please click on the following link:

http://www.prnewswire.com/news-releases/synthetic-biologics-reports-year-end-2013-financial-results-and-operational-update-253172521.html

 

*Please note – The C Diff Foundation does not endorse this product or any product and this posting is strictly for informational purposes only.